CY1108511T1 - Θεραπευτικες παραλλαγες της λιποπρωτεϊνικης λιπασης (lpl) - Google Patents

Θεραπευτικες παραλλαγες της λιποπρωτεϊνικης λιπασης (lpl)

Info

Publication number
CY1108511T1
CY1108511T1 CY20081101305T CY081101305T CY1108511T1 CY 1108511 T1 CY1108511 T1 CY 1108511T1 CY 20081101305 T CY20081101305 T CY 20081101305T CY 081101305 T CY081101305 T CY 081101305T CY 1108511 T1 CY1108511 T1 CY 1108511T1
Authority
CY
Cyprus
Prior art keywords
lpl
therapeutic
variations
lipoprotein fat
lipoprotein
Prior art date
Application number
CY20081101305T
Other languages
Greek (el)
English (en)
Inventor
Michael R Hayden
John J P Kastelein
Katherine Julia Diane Ashbourne Excoffon
Original Assignee
The University Of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of British Columbia filed Critical The University Of British Columbia
Publication of CY1108511T1 publication Critical patent/CY1108511T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • C12N9/20Triglyceride splitting, e.g. by means of lipase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034Lipoprotein lipase (3.1.1.34)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CY20081101305T 1999-06-24 2008-11-13 Θεραπευτικες παραλλαγες της λιποπρωτεϊνικης λιπασης (lpl) CY1108511T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99202048 1999-06-24
EP20000943499 EP1200117B1 (en) 1999-06-24 2000-06-23 Lipoprotein lipase (lpl) variant therapeutics

Publications (1)

Publication Number Publication Date
CY1108511T1 true CY1108511T1 (el) 2014-04-09

Family

ID=8240356

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101305T CY1108511T1 (el) 1999-06-24 2008-11-13 Θεραπευτικες παραλλαγες της λιποπρωτεϊνικης λιπασης (lpl)

Country Status (12)

Country Link
US (1) US20110201673A1 (enExample)
EP (1) EP1200117B1 (enExample)
JP (1) JP5095894B2 (enExample)
AT (1) ATE404217T1 (enExample)
AU (1) AU5799200A (enExample)
CA (1) CA2370081C (enExample)
CY (1) CY1108511T1 (enExample)
DE (1) DE60039880D1 (enExample)
DK (1) DK1200117T3 (enExample)
ES (1) ES2311464T3 (enExample)
PT (1) PT1200117E (enExample)
WO (1) WO2001000220A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044961B1 (en) * 2004-03-02 2013-07-17 Cellectar, Inc. Phospholipid analogues for the treatment of pancreatic, ovarian and colon cancers, melanomas, gliomas, and carcinosarcomas
WO2005123117A1 (en) * 2004-06-21 2005-12-29 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of non alcoholic steatotic hepatitis (nash)
PL1945779T3 (pl) 2005-10-20 2013-08-30 Uniqure Ip Bv Ulepszone wektory AAV produkowane w komórkach owadzich
CA2655957C (en) 2006-06-21 2016-05-03 Amsterdam Molecular Therapeutics (Amt) B.V. Vectors with modified initiation codon for the translation of aav-rep78 useful for production of aav in insect cells
PT2173888T (pt) 2007-07-26 2016-11-17 Uniqure Ip Bv Resumo
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2432497A1 (en) * 2009-05-18 2012-03-28 Amsterdam Molecular Therapeutics (AMT) IP B.V. Use of lipoprotein lipase (lpl) in therapy
RU2012100765A (ru) 2009-06-12 2013-07-20 Селлектар, Инк. Эфирные и алкильные фосфолипидные производные для лечения рака и визуализации и детектирования раковых стволовых клеток
US9228174B2 (en) 2010-03-11 2016-01-05 Uniqure Ip B.V. Mutated rep encoding sequences for use in AAV production
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
SG10201609345QA (en) 2012-02-07 2017-01-27 Global Bio Therapeutics Inc Compartmentalized method of nucleic acid delivery and compositions and uses thereof
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
ES2990174T3 (es) 2014-03-10 2024-11-29 Uniqure Ip Bv Vectores de AAV mejorados producidos en células de insecto
MA41035A (fr) * 2014-08-19 2017-08-15 Shire Human Genetic Therapies Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë
US12123030B2 (en) 2016-05-18 2024-10-22 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
CA3045551A1 (en) 2016-12-16 2018-06-21 Uniqure Ip B.V. Immunoadsorption
IL271957B2 (en) 2017-07-10 2024-02-01 Uniqure Ip Bv Means and methods for AAV-based gene therapy
EP3655538A1 (en) 2017-07-20 2020-05-27 uniQure IP B.V. Improved aav capsid production in insect cells
CN111527201A (zh) 2017-12-29 2020-08-11 优尼科Ip有限公司 修饰的病毒载体及其制备和使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU695618B2 (en) * 1994-04-11 1998-08-20 Baylor College Of Medicine Compositions and methods for gene therapy to treat disease
US5658729A (en) * 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis

Also Published As

Publication number Publication date
ES2311464T3 (es) 2009-02-16
PT1200117E (pt) 2008-11-26
AU5799200A (en) 2001-01-31
WO2001000220A3 (en) 2001-07-12
EP1200117A2 (en) 2002-05-02
WO2001000220A2 (en) 2001-01-04
JP5095894B2 (ja) 2012-12-12
EP1200117B1 (en) 2008-08-13
DE60039880D1 (en) 2008-09-25
ATE404217T1 (de) 2008-08-15
US20110201673A1 (en) 2011-08-18
JP2003503355A (ja) 2003-01-28
CA2370081A1 (en) 2001-01-04
DK1200117T3 (da) 2008-11-17
CA2370081C (en) 2014-06-03

Similar Documents

Publication Publication Date Title
CY1108511T1 (el) Θεραπευτικες παραλλαγες της λιποπρωτεϊνικης λιπασης (lpl)
ATE510851T1 (de) Auf peptiden basierende immunisierungstherapie zur behandlung von atherosklerose
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
BR9707819A (pt) Imunogenos peptidicos
BR0008188A (pt) Inibidores de fator de diferenciação de crescimento e usos para os mesmos
DE60221665D1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
MXPA03010103A (es) Peptidos y composiciones anti-microbianos.
DK0827509T3 (da) Modulering af cholesterylestertransferprotein-(CETP)-aktivitet
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
ATE285239T1 (de) Dna enthaltende impfstoffen
DK1352056T3 (da) Polypeptider, der er i stand til at fremkalde en immunreaktion mod cancer
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
BR9808226A (pt) Coronavìrus respiratório bovino como uma vacina
DE60107888D1 (de) Beta-Interferon zur Behandlung von Immunerkrankungen
DE69804302D1 (de) Kationische mittel zur transfektion von nukleinsäuren
DE60140950D1 (de) Neuer gentherapeutischer wirkstoff zur behandlung g
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
FR2813606B1 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
NO964894L (no) Rekombinante viruser, deres fremstilling samt anvendelse av genterapi
WO2007031574A3 (en) Therapeutic use of outer shigella protein f (os pf)
ATE323772T1 (de) Regulatorische sequenzen des humanen mcp-1 gens
ATE427961T1 (de) Mit fettzellendifferenzierung assoziiertes gen und protein
DE69807166D1 (de) Prostata-spezifische Antigen Inhibitore
ATE269897T1 (de) Methoden zur identifizierung und validierung von funktionellen zielen mittels intrameren oder in vivo selektion